Forbion portfolio company, CatalYm, was featured in a BioCentury article highlighting the growing momentum behind GDF15 as a promising therapeutic target for cancer-associated cachexia, an area of significant unmet medical need.
The article spotlights CatalYm as one of the leaders in the field, with its anti-GDF15 antibody visugromab advancing into Phase II/III development. CatalYm is evaluating visugromab both for its potential to address cachexia and, in combination with anti-PD-1 therapy, to enhance anti-tumor immune responses across multiple solid tumor indications.
BioCentury highlights emerging clinical data demonstrating visugromab’s potential to reverse pathological weight loss in cancer patients while also supporting anti-tumor activity. The feature underscores the unique role of GDF15 at the intersection of cancer-associated wasting and immune evasion, and the growing recognition of this pathway as a novel therapeutic opportunity.